On March 26 2020, Wellmarker Bio signed research collaboration agreement with AZothBio to develop a biomarker-based anti-cancer drugs using innovative AI platform (AiMol).

Wellmarker Bio agreed with AZothBio  to jointly develop a solid cancer target treatment that can overcome the resistance to the targeted therapy.

AZothBio’s virtual discovery technology known as ‘Generative-Adversal Network’ can predict the drug activation and not only does it create new drug candidates using new active compounds but it also allows to extract the characteristics of the existing compounds and mix with a novel one. The company expects to make innovative contributions to the new drug development with its advanced algorithms that can find and combine the characteristics of the compounds - creating virtual spaces accounting from 64 to 1124 dimensions.

The new drug that Wellmarker Bio is developing in collaboration with AZothBio is expected to be highly marketable as it has no competitive drug in the market and there is a wide range of patients that can be applied in the future through its indication expansion. By leveraging the AI platform, the company can reduce the development cost and time while gaining its market preposition.